-+ 0.00%
-+ 0.00%
-+ 0.00%

ZENAS BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF ZB021, A NOVEL, POTENTIALLY BEST-IN-CLASS ORAL IL-17AA/AF INHIBITOR

Reuters·05/13/2026 10:50:00

Please log in to view news